R2CHOP Appears Highly Active in DLBCL

Editor’s note: This article describes the results of a clinical trial—a research study with volunteer patients. The trial tested a new treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL). The new treatment consists of a combination of chemotherapy drugs known as R-CHOP, plus a new drug called lenalidomide (aka Revlimid). R-CHOP is a standard treatment for DLBCL. The results were promising, but more research will need to be done to figure out whether the new treatment is indeed better than the old. The results also showed that adding lenalidomide might work better for a certain sub-group of patients known as the non-GCB subtype.

“The combination of lenalidomide and R-CHOP demonstrated considerable activity in patients with newly diagnosed diffuse large B-cell lymphoma, according to results of a phase 2 study.

“The development of a more effective initial therapy is essential to improve long-term outcomes of patients with diffuse large B-cell lymphoma (DLBCL), Grzegorz S. Nowakowski, MD, of the division of hematology at Mayo Clinic in Rochester, Minn., and colleagues wrote.

“Prior studies demonstrated lenalidomide (Revlimid, Celgene) has considerable single-agent activity in relapsed DLBCL. Lenalidomide also can be combined with R-CHOP — which consists of rituximab (Rituxan; Genentech, Biogen Idec), cyclophosphamide, doxorubicin, vincristine and prednisone) — to form a novel combination known as R2CHOP.

“In the current study, Nowakowski and colleagues evaluated the efficacy of R2CHOP in 60 patients with newly diagnosed DLBCL. The median age of patients was 65 years; 70% were aged older than 60 years, and 9% were aged ≥80 years.”